Using Personalized Drug Tapering for Rheumatoid Arthritis
Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage: the MONITORA Study
Recruiting
Phase 4
Interventional Study
Arthritis, Rheumatoid
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 180 (estimated)
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne · Other
Who this trial is looking for
This trial is looking for adults with rheumatoid arthritis who have been in remission. Participants will help researchers understand how to safely reduce their medication dosage.
Are You a Good Fit for This Trial?
You may be able to join if
- I am over 18 years old
- I have been diagnosed with rheumatoid arthritis
- I have been in remission for at least 6 months
- I have been treated with adalimumab for at least 6 months
- I take adalimumab every 2 or 3 weeks
- I have a negative pregnancy test if I can become pregnant
- I am covered by a social security scheme
- I have signed the informed consent
You may not be able to join if
- I cannot understand or sign the informed consent
- I am currently pregnant, breastfeeding, or plan to become pregnant in the next 15 months
- I have fibromyalgia along with my rheumatoid arthritis
- I have taken any prednisone for rheumatoid arthritis in the last 6 months
- I am in custody or under guardianship
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Rheumatoid arthritis (RA) is the most common inflammatory joint disorder. Since twenty year and the use of synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and biological (b)DMARD, remission can be reached. When remission is obtained, the physician has no recommendations for managing a step-down, and future guidelines will be useful to assist the clinician. Recent data suggest that tape…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patient over 18 years of age
* Patients with a diagnosis of RA according to ACR/EULAR 2010 criteria
* Remission according to DAS28\<=2.6 for at least 6 months
* Patient treated with ADA for at least 6 months. The patient is treated according to one of the following two strateg…
Contacts